As a chemotherapy drug sensitizer, ATO can inhibit the electron transfer of respiratory chain coenzyme Q in liver cancer cells, reduce cell respiration, and inhibit the synthesis of mitochondrial respiratory chain complex I and complex III, thus inhibiting the oxidative phosphorylation process of cells, inhibiting the mitochondrial function of liver cancer cells, and reshaping the tumor microenvironment [16,17]. Here, NDUFV1 is linked to liver cancer.